<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 28, 1996
------------------
BIOJECT MEDICAL TECHNOLOGIES INC.
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Oregon
----------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-15360 93-1099680
------------------------ --------------------------------
(Commission File Number) (IRS Employer Identification No.)
7620 SW Bridgeport Road
Portland, Oregon 97224
- --------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (503) 639-7221
--------------
N/A
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE> 2
ITEM 5. OTHER EVENTS
TEXT OF PRESS RELEASE
BIOJECT ANNOUNCES CANCELLATION OF CONTRACT WITH SCHERING AG
Portland, Ore/January 28, 1997 - Bioject Medical Technologies Inc.
(NASDAQ:BJCT), the leading manufacturer of jet injection devices for needle-
free subcutaneous and intramuscular injections, reported that it has received
notice that its contract with Schering AG, Germany, and Schering's United
States subsidiary, Berlex Laboratories, will be cancelled. Under provisions
of the contract, Schering AG has the option of cancelling the agreement if the
FDA requires extensive clinical studies beyond an originally planned safety
study. Schering AG recently received a review letter from the FDA which would
have required Schering to conduct additional material clinical studies in
order to use non-traditional delivery mechanisms with its Betaseronr product.
Jim O'Shea, Bioject's chairman and chief executive officer stated, "We are
surprised and disappointed with Schering's decision to cancel the contract but
we understand that the uncertain regulatory clearance schedule has been a
significant factor in this decision. It does not diminish Bioject's
commitment to extending our needle-free technology to other applications. We
retain rights to the self-injection technology and are actively seeking other
strategic partners for whom such a system would provide a competitive
advantage. Schering and Berlex Laboratories have been good companies to work
with and we wish them every success in the future."
Under terms of the contract, Schering must convert its $1.6 million note due
from Bioject into approximately 460,000 shares of Bioject common stock at a
conversion price of $3.50 per share. In addition, Schering is obligated to
pay Bioject for all product ordered to date.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOJECT MEDICAL TECHNOLOGIES INC.
Date: January 28, 1997 By /s/ Peggy J. Miller
----------------------------------
Peggy J. Miller
Vice President, Chief Financial
Officer, Secretary/Treasurer
